Skip to content

Late-stage study of Humanigen lead drug in Covid to continue unchanged

September 14, 2020

The Independent Data Safety Monitoring Board (DSMB) has completed pre-specified interim analysis for Humanigen’s (OTCQB:HGEN) lead drug candidate lenzilumab Phase 3 trial for COVID-19 and recommended that the study continue unmodified.

The DSMB conducted the analysis after 50% of the expected recoveries were captured, and assessed the Phase 3 trial data for safety, futility, sample size and power assumptions.

The company expects to complete the targeted enrollment of 300 patients this month, with topline data expected in the next quarter.

Lenzilumab is a Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody.

Recently, the company announced lenzilumab demonstrated positive effect in COVID-19 in case-control study

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: